Effect Of Combination Therapy With Intratympanic Methylprednisolone & Batroxobin In Sudden Senorineural Hearing Loss Patient With Diabetes

Objective : To summarise the outcomes of combination therapy with intratympanic methylprednisolone and batroxobin and to provide the reference for diagnosis and treatment and the related factors on the prognosis in Sudden Sensorineural Hearing Loss patient with diabetes.Methods : A total of 52 Sudden sensorineural hearing loss patients with diabetes, 29 Males(55.8%) and 23 Females(44.2%) were retrospectively recruited in the study from Jan 2013 to Dec 2015. And then subjected to combined treatment with intratympanic methylprednisolone and batroxobin. The relativity between presence or absence of tinnitus, vertigo and dizziness and patients onset of symptoms to therapy, duration and age of onset and curative effect were analyzed.Intervention : Injection of methylprednisolone 40mg(0.5ml) solution was administered into the posterior inferior quadrant of tympanic membrane via 1ml narrow-syringe to fill middle ear space Keeping affected ear in upward position for 30 minutes,try to avoid swallowing, Qod *5 times. Batroxobin(10 m U) was given intravenously on the first day and then(5m U)every other day thereafter upto 5 to 7 times.Main Outcome Measures : Hearing levels and related factors for prognosis after therapy.Results : Statistical analyses showed better hearing improvement in patients who started therapy soon after onset of symptoms(x2 = 7.834, p = 0.020). Patients whose duration of diabetes were shorter had better response of recovery rates compared to patients with longer duration(x 2 = 4.690, p = 0.030). Patients younger than 60 years of age had shown significantly greater hearing improvement than in patients 60 years of age or older.(x 2 = 6.385, p = 0.012).Conclusion : Sudden sensorineural hearing loss patients with diabetes mellitus can be treated with combination therapy of intratympanic methylprednisolone and batroxobin without any obvious complications. It is reasonable to expect the treatment prognosis correlations with the interval from onset to treatment, age and duration of diabetes in sudden sensorineural hearing loss.